Markets:

Overview

News

Currencies

International

Treasuries

Enanta Pharmaceuticals, Inc. - Common Stock (NQ:ENTA)

11.55 -0.63 (-5.17%)

Delayed Quote Updated: 4:00 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enanta Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway ↗

June 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) AngioDynamics, Inc. (NASDAQ...

Via Benzinga

Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral Hepatitis B Virus RNA Destabilizer, at the European Association for the Study of the Liver (EASL) International Liver Congress™

June 23, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge ↗

May 01, 2021

Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name...

Via Benzinga

Enanta Pharmaceuticals Reports Positive Data from Phase 1b Study of EDP-514, a Hepatitis B Virus (HBV) Core Inhibitor, in Viremic Chronic HBV Patients

June 22, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Participate in Two Investor Conferences in June

June 10, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral Hepatitis B Virus RNA Destabilizer, at the International Liver Congress™ 2021 Sponsored by the European Association for the Study of the Liver

June 03, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

May 11, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta's EDP-514 Four-Week Treatment Shows Around 10 Time Reduction In Hepatitis B Virus RNA ↗

May 07, 2021

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced data from the first two dose cohorts of Part 2 of its Phase 1b study evaluating EDP-514 in chronic...

Via Benzinga

Enanta Pharmaceuticals Inc (ENTA) Q2 2021 Earnings Call Transcript ↗

May 07, 2021

ENTA earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET

May 06, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta Pharmaceuticals Reports Positive Data from Part 2 of its Phase 1b Study of EDP-514 in Chronic Hepatitis B Virus Patients on Treatment with a Nucleoside Reverse Transcriptase Inhibitor

May 06, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

Enanta to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2021

April 29, 2021

From Enanta Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom ↗

May 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.